CEO Total Pay
$20.1M
FY2022 Summary Compensation
Data updated July 2026
Open-data reference.
Horizon Therapeutics Public Ltd Co, a chemicals & pharmaceuticals company, reported a CEO-to-worker pay ratio of 76:1 in FY2022. The CEO received total compensation of $20.1M, while the median employee earned $264,751 annually. This is above the Chemicals & Pharmaceuticals industry median of 44:1 across 165 companies. Data sourced from SEC EDGAR proxy (DEF 14A) filings.
A component-level pay breakdown is not reported in Horizon Therapeutics Public Ltd Co's structured SEC pay-ratio disclosure. See our methodology →
Horizon Therapeutics Public Ltd Co's CEO-to-worker pay ratio of 76:1 means that the CEO earned 76 times more than the company's median employee in FY2022.
The median employee at Horizon Therapeutics Public Ltd Co earned $264,751 annually. At that wage, it would take a median employee approximately 76 years to earn what the CEO earned in a single year.
SEC rules let each company choose its own methodology for identifying the "median employee" (measurement date, statistical sampling, whether part-time pay is annualized, and a de minimis exemption for up to 5% of non-U.S. employees), so a higher ratio doesn't automatically mean less-fair pay practices, it can also reflect workforce mix (a large offshore, outsourced, or part-time-heavy workforce lowers the reported median and raises the ratio for reasons unrelated to CEO compensation itself).
CEO Total Pay
$20.1M
FY2022 Summary Compensation
Pay Ratio
76:1
Near industry median
According to the 2022 DEF 14A proxy statement filed with the SEC, Horizon Therapeutics Public Ltd Co (CIK 1492426) reported the CEO's total compensation at $20.1M. The proxy statement's structured pay-ratio disclosure reports this total but does not break it down by salary, bonus, equity, or other components. The median employee at the firm, the reference point mandated by Section 953(b) of the Dodd-Frank Act, earned $264,751 over the same fiscal year, producing the headline CEO-to-worker pay ratio of 76:1 that this page tracks.
Horizon Therapeutics Public Ltd Co operates in the Chemicals & Pharmaceuticals sector and is headquartered in L2. Across the Chemicals & Pharmaceuticals industry (SIC 28), 165 SEC-reporting companies disclosed pay ratios in FY2025, with a median of 44:1 and an average of 75:1. Median industry CEO pay was $8.3M, so Horizon Therapeutics Public Ltd Co's $20.1M sits above that typical figure.
This proxy was filed on 2023-06-30; all figures on this page come directly from that public filing and can be verified against the DEF 14A on the SEC EDGAR system.
Total compensation reported under Item 402 of Regulation S-K reflects grant-date fair value for equity awards, not realized pay, so a CEO may eventually cash in more, or less, depending on stock performance and vesting. The pay ratio itself is calculated against a single median employee chosen under rules that allow statistical sampling, and companies may update methodology year to year.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed July 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
Every figure on PlainCEOPay is rendered directly from SEC EDGAR executive compensation filings, no number is typed in by an editor. Executive pay figures are computed directly from SEC EDGAR filings, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.